Egle Therapeutics Identifies First Novel Regulatory T-Cell Targets In Research Alliance With Takeda

Egle Therapeutics Identifies First Novel Regulatory T-Cell Targets In Research Alliance With Takeda

By, Admin 30 November 2020

Egle Therapeutics Sas (Egle), An Emerging Biotechnology Company Focused On Developing First-In Class Immunotherapies Targeting Immune Suppressor Regulatory T-Cells (Tregs) For Oncology And Autoimmune Diseases, Today Announces That It Has Achieved The First Milestone In Its Strategic Research Alliance With Takeda Pharmaceutical Company Limited (&Ldquo;Takeda&Rdquo;). In The Course Of The Strategic Research Alliance That Was Announced In June 2020, Egle Will Validate Novel Tumor-Infiltrating Regulatory T-Cell (Treg) Targets Against Which Takeda Will Develop Potential Therapies.Egle Has Leveraged Its Unique Bioinformatic And Translational Capabilities To Successfully Identify Targets That Will Now Be Pursued Under The Terms Of The Alliance. Upon Achievement Of The Target Identification, Egle Will Receive An R&Amp;D Milestone Payment And Investment From Takeda.Luc Boblet, Ceo Of Egle, Commented &Ldquo;Reaching This First Technical Milestone Marks Our Positive Progress Towards Our Joint Goal With Takeda, Of Creating The Next Generation Of Differentiated Immunotherapies Against Tregs, And Provides Strong Validation Of The Work Being Done At Egle. We Look Forward To Continuing Our Productive Alliance With Takeda While Pushing Further Our Internal Programs Through The Equity Component Of The Alliance.&Rdquo;&Ldquo;We Have Made Great Progress In Our Collaboration With Egle And Are Thrilled With The Speed Of Which We Identified Our First Novel Treg Targets,&Rdquo; Said LoÏC Vincent, Head, Oncology Drug Discovery Unit At Takeda. &Ldquo;We Hope To Build Upon This Momentum In The Next Phase Of Our Partnership To Enable And Ultimately Deliver New Immuno-Oncology Therapeutic Options.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!